<PAGE> 1
SECURITIES & EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) November 28, 1995
-------------------------------
MERCK & CO., Inc.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
New Jersey
- --------------------------------------------------------------------------------
(State or other jurisdiction of incorporation)
1-3305 22-1109110
------------------------ ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
One Merck Drive, PO Box 100, Whitehouse Station, NJ 08889-0100
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code (908) 423-1000
-----------------------------
<PAGE> 2
Item 5. Other Events
Incorporated by reference is that portion of a press release issued by the
Registrant on November 28, 1995 concerning the Registrant's announcement of
the approval by its Board of Directors of a new $3 billion treasury stock
purchase program. The press release is attached as Exhibit 99.
Item 7. Financial Statements and Exhibits
(c) Exhibit
Exhibit 99 - Press release issued November 28, 1995.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Report to be signed on its behalf by the
undersigned hereunto duly authorized.
MERCK & CO., Inc.
By: /s/ Nancy V. Van Allen
-------------------------------
Nancy V. Van Allen
Assistant Secretary
December 4, 1995
<PAGE> 3
EXHIBIT INDEX
<TABLE>
<CAPTION>
Method
Exhibit of
Number Description Filing
- ------- ----------- ------
<S> <C> <C>
99 Press release issued November 28, 1995. Filed with
this document.
</TABLE>
<PAGE> 1
Exhibit 99
FOR IMMEDIATE RELEASE
Contacts: John Doorley, Press Contact
Whitehouse Station, N.J. -- (908) 423-4081
Home -- (908) 232-2052
Jim Hinrichs, Investor Contact
Whitehouse Station, N.J. -- (908) 423-6883
MERCK BOARD DECLARES DIVIDEND AND APPROVES $3 BILLION TREASURY
STOCK PURCHASE PROGRAM
WHITEHOUSE STATION, NJ, November 28, 1995 -- The Board of Directors of
Merck & Co., Inc., in two separate actions today, declared a quarterly dividend
of 34 cents a share and approved a new $3 billion treasury stock purchase
program.
The Board declared a quarterly dividend of 34 cents a share on the Company's
common stock for the first quarter of 1996. The 34-cent dividend is payable
January 2, 1996 to stockholders of record at the close of business on December
8, 1995.
The Board of Directors of Merck & Co., Inc. today also approved purchases over
time of up to an additional $3 billion of its common stock for its treasury.
The Company is currently completing purchases under a November 1994, $2 billion
authorization. Through September 30, 1995 the Company spent $1.3 billion to
acquire 29 million shares under the November 1994, $2 billion authorization.
Under prior approvals during the period 1985 through 1994, the Company spent
$4.7 billion to acquire 223 million shares of its stock on the open market.
Merck currently has approximately 1,230 million shares outstanding.
- more -
<PAGE> 2
- 2 -
Treasury stock purchases will be made on the open market in block transactions
and in privately negotiated transactions. Purchases may be suspended from time
to time or discontinued. Shares acquired will be available for use under the
Company's employee benefit programs and for other general corporate purposes.
Merck & Co., Inc. is a leading research-driven pharmaceutical products and
services company. Merck discovers, develops, manufacturers and markets a broad
range of innovative products to improve human and animal health. The
Merck-Medco Managed Care Division manages pharmacy benefits for employers,
insurers and other plan sponsors, encouraging the appropriate use of medicines
and providing disease management programs. Through these complementary
capabilities, Merck works to improve quality of life and contain overall
health-care costs.
###
